All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 6th World Congress on Controversies in Multiple Myeloma (COMy) the Multiple Myeloma Hub spoke to Giampaolo Merlini, University of Pavia, Pavia, IT, about the latest advances in AL amyloidosis treatment.
Latest advances in AL amyloidosis treatment
During this year, three clinical trials evaluating combinations of different drugs in patients with AL amyloidosis have been concluded. Giampaolo Merlini discusses the promising results of these clinical trials, which contributed to improving patient care.
TOURMALINE-AL1 | Ixazomib-dexamethasone for relapsed/refractory systemic AL amyloidosis
The results from the first planned interim analysis of the TOURMALINE-AL1 trial, comparing the combination of ixa plus dexamethasone to physician’s choice of...
Results of the safety run-in phase of the ANDROMEDA trial in patients with newly diagnosed AL amyloidosis
Summary of the results of the safety run-in phase of the phase III ANDROMEDA study comparing therapeutic regimens for the treatment of patients...
Subscribe to get the best content related to multiple myeloma delivered to your inbox